Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pathologic Complete Response × Induction Chemotherapy × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 2 Turcot syndrome 1 Pathologic Complete Response 1 Neuroectodermal Tumors, Primitive 1 Medulloblastoma 1 Esophagitis 1 Esophageal Neoplasms 1 ESCC 1 Brain Neoplasms 1 Anus Neoplasms 1

Interventions

Carboplatin 4 pembrolizumab 3 Paclitaxel 3 Capecitabine 3 Azacitidine 3 venetoclax 2 pertuzumab 2 olaparib 2 durvalumab 2 Trastuzumab 2 Standard of Care 2 Oxaliplatin 2 Observation 2 Irinotecan 2 Immunotherapy 2 Immune Checkpoint Inhibitors 2 Chemoradiotherapy 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 trebananib 1 trastuzumab duocarmazine 1 tislelizumab 1 tegafur-gimeracil-oteracil 1 taxane 1 talazoparib 1 tagraxofusp 1 sarilumab 1 sargramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07472868 2026-03-16

MEND-IT II

Catharina Ziekenhuis Eindhoven

Phase 3 Not yet recruiting

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon ⚡